WASHINGTON — More than six years after COVID-19 transformed the U.S. healthcare system, the federal government is moving to formally close one of the last major regulatory chapters of the pandemic: the emergency authorization system that helped bring vaccines, treatments, tests and medical devices to Americans at unprecedented speed.
The Department of Health and Human Services announced in June that the circumstances supporting COVID-19 emergency-use declarations for drugs, biological products and medical devices no longer exist. But the government is not ending every authorization immediately. Instead, federal officials have established transition periods designed to give manufacturers, healthcare providers and patients time to move products toward traditional regulatory pathways.
For drugs and biological products, the COVID-19 emergency-use declaration is scheduled to terminate on June 29, 2027.
For medical devices, including certain COVID-19 diagnostic tests and protective equipment, the corresponding declarations are scheduled to terminate on December 26, 2026.
The staggered timeline means the pandemic’s emergency regulatory framework is entering its final phase rather than disappearing overnight.
A Major Shift From Emergency Regulation
Emergency Use Authorization, commonly known as EUA, became one of the most important regulatory mechanisms during the COVID-19 crisis.
The authority allowed the FDA to authorize certain unapproved medical products or unapproved uses of approved products when statutory emergency conditions were met and there were no adequate, approved and available alternatives.
That framework helped accelerate access to COVID-19 vaccines, treatments, diagnostic tests and other medical products.
But federal health officials now argue that the conditions that justified the extraordinary measures have fundamentally changed.
HHS Secretary Robert F. Kennedy Jr. signed the June determinations ending the COVID-19 EUA declarations, saying emergency authorities should be temporary and targeted.
The Pandemic Emergency Is Being Replaced by Normal Regulation
The federal government’s decision does not mean COVID-19 has disappeared.
Instead, it represents a judgment that the United States no longer needs the same broad emergency regulatory framework created during the height of the pandemic.
The FDA says approved, cleared and licensed COVID-19 products are now widely available through traditional regulatory channels.
Manufacturers have also had years to prepare products for the transition.
That distinction is important.
COVID-19 remains a public-health concern, but federal regulators are increasingly treating medical products for the disease within the normal drug, biologics and medical-device systems.
Existing Products Are Not Automatically Disappearing
For consumers, the most important point is that the end of the EUA declarations does not mean all COVID-19 vaccines, treatments or tests will suddenly become unavailable.
Products that have received traditional FDA approval, clearance or licensure can continue operating under those regulatory pathways.
The FDA’s current COVID-19 information pages list approved vaccines and treatments separately from products that were authorized exclusively through emergency-use authority.
That means the regulatory transition primarily affects products whose legal status depends on the COVID-19 emergency declarations.
COVID Vaccines Enter a New Regulatory Era
The shift is occurring alongside another major change in COVID-19 vaccine policy.
The FDA has moved ahead with the 2026-2027 COVID-19 vaccine formula, recommending that manufacturers target the JN.1-lineage XFG variant to better match viruses circulating in the United States.
The agency’s advisory committee reviewed available data on circulating variants, vaccine effectiveness, immune responses and other scientific evidence before recommending the updated formulation.
That work demonstrates how COVID-19 vaccines are increasingly being managed through an ongoing regulatory and scientific process rather than the extraordinary emergency system used in 2020 and 2021.
Updated Vaccines Have Now Been Approved
The FDA approved updated COVID-19 vaccines for the 2026-2027 season from Moderna, Novavax-Sanofi and Pfizer-BioNTech in August.
The approvals are designed to provide protection against currently circulating variants and prepare the country for the fall and winter respiratory-virus season.
The approvals also illustrate the distinction between FDA-approved vaccines and products that remain under emergency authorization.
As the EUA system winds down, the traditional approval pathway is increasingly becoming the primary route for COVID-19 vaccine products.
Medical Devices Face a Faster Deadline
The transition is moving faster for medical devices.
The FDA says the COVID-19 emergency declarations covering in-vitro diagnostic tests, personal respiratory protective devices and certain medical devices will terminate on December 26, 2026.
The FDA has emphasized that the end of the COVID-19 public health emergency in May 2023 did not itself eliminate the agency’s ability to issue emergency-use authorizations.
Existing EUAs continued under the separate statutory emergency authority until the new 2026 termination decisions.
COVID Testing Is Part of the Transition
Diagnostic testing is one of the areas most directly affected by the changing rules.
During the pandemic, emergency authorization enabled manufacturers to bring large numbers of COVID-19 tests to the U.S. market quickly.
As the emergency framework ends, manufacturers may need to pursue traditional regulatory pathways if they want their products to remain available under a permanent authorization.
The FDA has been providing transition information to help companies understand what happens to COVID-related device authorizations as the federal declarations expire.
Why the Government Is Using a Transition Period
Ending emergency authority immediately could create unnecessary disruption.
Manufacturers need time to evaluate regulatory requirements.
Hospitals and healthcare systems need time to update procurement decisions.
Distributors need to understand which products remain legally available.
Patients also need continuity of access.
The HHS decision therefore includes advance notice periods specifically designed to allow the healthcare system to move away from products authorized solely under COVID-19 emergency authorities.
The FDA Will Continue Reviewing Products
The end of the emergency declaration does not mean the FDA will stop evaluating COVID-19 products.
The agency says it will continue working with manufacturers seeking traditional approval, clearance or licensure.
That could include products that previously relied on emergency authorization but now have enough data and manufacturing experience to pursue standard regulatory approval.
For manufacturers, the transition could therefore become an opportunity rather than simply a regulatory deadline.
What Happens to Emergency-Only Products?
Products that depend exclusively on the COVID-19 EUA authority will face a different future.
Once the relevant declaration terminates, the FDA says the COVID-19 EUAs listed under that authority will no longer be in effect.
For drugs and biological products, that date is June 29, 2027.
For devices, the date is December 26, 2026.
Manufacturers that want to continue marketing such products will need to use an appropriate traditional regulatory pathway.
The Change Reflects a Different Public-Health Environment
The EUA system was created for a very different moment.
In 2020, SARS-CoV-2 was a newly recognized threat, vaccines were still being developed and healthcare systems were struggling with rapidly rising infections.
The government needed mechanisms that could move medical countermeasures into use quickly.
Six years later, the United States has multiple FDA-approved COVID-19 vaccines and treatments, extensive clinical experience and a much larger body of evidence about the disease.
The federal government says those developments justify returning to standard regulatory processes.
The Debate Over Pandemic Policy Is Not Over
Even as emergency authorizations wind down, the political debate surrounding COVID-19 policy remains intense.
Questions about vaccine recommendations, federal health agencies and pandemic preparedness continue to divide policymakers and the public.
The end of EUA declarations therefore represents both a regulatory change and a symbolic milestone.
It marks the government’s formal move away from some of the extraordinary legal authorities created during the pandemic.
Trust Will Remain a Major Issue
The transition also comes at a sensitive time for federal health agencies.
Public confidence in government health institutions has faced significant challenges in recent years.
That makes transparency especially important as regulators explain which products remain approved, which products are transitioning and which emergency authorizations will eventually expire.
Clear communication will be critical to preventing consumers from confusing the end of an EUA with the end of COVID-19 treatment or vaccination.
Manufacturers Face New Compliance Decisions
For pharmaceutical and medical-device companies, the next year will involve important regulatory decisions.
Manufacturers relying on emergency authorization must determine whether to pursue traditional approval or discontinue the product.
That decision can depend on clinical evidence, manufacturing capacity, market demand and the costs associated with completing a conventional FDA review.
Companies that remain in the market will have to meet the applicable standards for their product category.
Hospitals and Pharmacies Will Also Adjust
Healthcare providers are another important part of the transition.
Hospitals and pharmacies will need to track the regulatory status of products they purchase and administer.
For COVID-19 vaccines, the transition is less disruptive because multiple products have traditional FDA approval.
For certain tests or specialized emergency-use products, however, procurement departments may need to identify alternatives.
The Emergency System Changed American Healthcare
The EUA system will ultimately be remembered as one of the defining regulatory features of the COVID-19 era.
It demonstrated how quickly federal agencies could create pathways for medical products during an emergency.
But it also raised difficult questions about how much regulatory flexibility should be used during a crisis and how those extraordinary authorities should eventually be withdrawn.
The 2026 transition is effectively the final test of that exit strategy.
The Government Is Not Declaring COVID-19 Over
It is important to distinguish the regulatory decision from a declaration that COVID-19 is no longer a health threat.
The federal government is ending specific emergency-use declarations because it says the circumstances that originally justified them no longer exist.
COVID-19 vaccines remain available, updated vaccines continue to be developed and approved, and the FDA continues monitoring the virus and vaccine performance.
The disease itself remains part of the broader U.S. respiratory-virus landscape.
What Americans Should Expect
For most Americans, the transition is likely to be relatively gradual.
People receiving FDA-approved COVID-19 vaccines or treatments should not assume those products are being withdrawn simply because emergency authorizations are ending.
Instead, consumers should pay attention to the specific regulatory status of products and rely on information from the FDA, healthcare providers and other trusted sources.
The biggest changes are likely to occur among products whose availability depends exclusively on COVID-19 EUA authority.
The Bottom Line
The United States is moving toward the final phase of its COVID-19 emergency authorization system, with federal officials setting firm dates for the termination of the emergency declarations that helped accelerate access to vaccines, treatments, tests and medical devices during the pandemic.
HHS determined in June 2026 that the circumstances supporting the COVID-19 emergency-use declarations for drugs, biological products and medical devices no longer exist. The transition will occur gradually, with drug and biological-product declarations ending June 29, 2027, while medical-device declarations are scheduled to end December 26, 2026.
The FDA is simultaneously moving COVID-19 vaccines and other products through traditional regulatory pathways. Updated 2026-2027 vaccines have been developed around the XFG variant, reflecting the agency’s continued monitoring of how SARS-CoV-2 evolves.
For manufacturers, the coming months will be a period of regulatory transition.
For healthcare providers, the priority will be maintaining access to products that remain medically necessary while replacing products that cannot transition to traditional authorization.
And for patients, the message is straightforward: the end of emergency-use declarations does not mean the end of COVID-19 care.
Instead, it marks the government’s move from an emergency regulatory framework toward a more conventional system in which vaccines, treatments, tests and medical devices are expected to operate under standard FDA rules.
More than six years after the pandemic began, Washington is now closing one of the most consequential chapters of the COVID-19 response—while leaving behind a regulatory system that could influence how the United States responds to the next major public-health emergency.
Source angle: HHS termination determinations, FDA COVID-19 EUA records, FDA 2026-2027 vaccine updates and federal transition timelines for COVID-19 medical products.
